tiprankstipranks
Advertisement
Advertisement
Nuvation Bio: FDA accepts sNDA with updated data for IBTROZI
PremiumThe FlyNuvation Bio: FDA accepts sNDA with updated data for IBTROZI
1M ago
Analyst Reiterates Buy on Nuvation Bio, Maintains $17 Price Target on Long-Term IBTROZI Growth Potential
Premium
Ratings
Analyst Reiterates Buy on Nuvation Bio, Maintains $17 Price Target on Long-Term IBTROZI Growth Potential
1M ago
Yaron Werber Reiterates Buy on Ibtrozi Maker, Citing Growing First‑Line Adoption and Market Share Gains in ROS1‑Positive Lung Cancer Despite Near‑Term Estimate Cuts
Premium
Ratings
Yaron Werber Reiterates Buy on Ibtrozi Maker, Citing Growing First‑Line Adoption and Market Share Gains in ROS1‑Positive Lung Cancer Despite Near‑Term Estimate Cuts
1M ago
Nuvation Bio price target raised to $13 from $12 at RBC Capital
PremiumThe FlyNuvation Bio price target raised to $13 from $12 at RBC Capital
3M ago
Nuvation Bio price target lowered to $7 from $10 at UBS
Premium
The Fly
Nuvation Bio price target lowered to $7 from $10 at UBS
3M ago
Closing Bell Movers: MongoDB down over 20% after soft Q1 guidance
Premium
The Fly
Closing Bell Movers: MongoDB down over 20% after soft Q1 guidance
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100